Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.35 +9.8%	$1.44	$0.65 ▼ $17.00	$14.35M	1.19	1.19 million shs	2.12 million shs
MRKR Marker Therapeutics	$1.29 +6.6%	$1.46	$0.95 ▼ $5.95	$16.69M	1.45	538,513 shs	101,555 shs
NBY NovaBay Pharmaceuticals	$0.91 -14.9%	$0.64	$0.44 ▼ $1.25	$5.30M	0.4	1.31 million shs	1.67 million shs
NEUP Neuphoria Therapeutics	$7.18 +3.8%	$7.44	$2.12 ▼ $12.55	$13.50M	0.53	231,079 shs	9,275 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	+0.41%	-6.11%	-15.75%	+74.96%	-91.77%
MRKR Marker Therapeutics	+4.31%	-3.20%	-23.42%	+6.14%	-65.72%
NBY NovaBay Pharmaceuticals	+3.88%	+76.92%	+66.90%	+87.82%	+97.78%
NEUP Neuphoria Therapeutics	-0.29%	-14.57%	-10.13%	+2.06%	+691,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	2.986 of 5 stars	3.3	4.0	0.0	2.3	0.8	1.3
MRKR Marker Therapeutics	3.6109 of 5 stars	3.8	2.0	3.9	2.0	0.0	0.0
NBY NovaBay Pharmaceuticals	0.3826 of 5 stars	1.5	0.0	0.0	0.6	0.0	1.3
NEUP Neuphoria Therapeutics	1.3775 of 5 stars	3.5	0.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,825.93% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	920.67% Upside
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-6.60% Downside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	192.48% Upside

Current Analyst Ratings Breakdown

Latest NBY, MRKR, NEUP, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$6.35 per share	N/A
MRKR Marker Therapeutics	$6.59M	2.53	N/A	N/A	$0.81 per share	1.59
NBY NovaBay Pharmaceuticals	$9.78M	0.54	N/A	N/A	$4.25 per share	0.21
NEUP Neuphoria Therapeutics	$10K	1,349.84	N/A	N/A	$15.85 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.08	N/A	N/A	-60.03%	-33.83%	N/A
MRKR Marker Therapeutics	-$10.73M	-$1.37	N/A	N/A	N/A	-271.12%	-114.59%	-90.31%	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
NEUP Neuphoria Therapeutics	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/29/2025 (Estimated)

Latest NBY, MRKR, NEUP, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	MRKR Marker Therapeutics	-$0.55	-$0.29	+$0.26	-$0.29	$0.72 million	$0.86 million
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.47	0.14
MRKR Marker Therapeutics	N/A	3.45	6.79
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
NEUP Neuphoria Therapeutics	N/A	11.01	11.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
MRKR Marker Therapeutics	22.39%
NBY NovaBay Pharmaceuticals	23.25%
NEUP Neuphoria Therapeutics	15.90%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
MRKR Marker Therapeutics	7.80%
NBY NovaBay Pharmaceuticals	0.10%
NEUP Neuphoria Therapeutics	0.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
MRKR Marker Therapeutics	60	12.94 million	11.93 million	Not Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A

NBY, MRKR, NEUP, and CTXR Headlines

Recent News About These Companies

Dementia Associated with Alzheimer’s Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight

July 17, 2025 | finance.yahoo.com

NEUP Neuphoria Therapeutics Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Neuphoria Therapeutics Inc. (NEUP) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025 | globenewswire.com

Neuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business Updates

May 21, 2025 | finanznachrichten.de

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025 | globenewswire.com

Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

Neuphoria Therapeutics provides review of 2024, highlights 2025 plans

April 16, 2025 | markets.businessinsider.com

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

April 15, 2025 | globenewswire.com

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

March 3, 2025 | globenewswire.com

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

February 12, 2025 | globenewswire.com

Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going

February 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBY, MRKR, NEUP, and CTXR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.35 +0.12 (+9.76%)

Closing price 04:00 PM Eastern

Extended Trading

$1.35 +0.00 (+0.07%)

As of 07:19 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Marker Therapeutics NASDAQ:MRKR

$1.29 +0.08 (+6.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.24 -0.05 (-3.80%)

As of 06:52 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

NovaBay Pharmaceuticals NYSE:NBY

$0.91 -0.16 (-14.94%)

As of 04:00 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Neuphoria Therapeutics NASDAQ:NEUP

$7.18 +0.26 (+3.76%)

As of 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time